The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia

Gulnara Aghayeva; Mario Rizzetto; Necati Ormeci; Adela Turcanu; Zaigham Abbas; Essam Bedewy

doi:10.1016/B978-0-443-26710-9.00023-7

The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia

Gulnara Aghayeva, Mario Rizzetto, Necati Ormeci, Adela Turcanu, Zaigham Abbas, Essam Bedewy

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.

Original language	English (UK)
Title of host publication	Hepatology
Subtitle of host publication	an Evidence-Based Clinical Compendium: Volume 1-2
Publisher	Elsevier
Pages	655-673
Number of pages	19
Volume	1-2
ISBN (Electronic)	9780443300523
ISBN (Print)	9780443300530
DOIs	https://doi.org/10.1016/B978-0-443-26710-9.00023-7
Publication status	Published - 1 Jan 2024
Externally published	Yes

Keywords

Anti-HDV
HCC
HDV epidemiology
HDV lifecycle
HDV therapy
Hepatitis D virus
Prevalence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-443-26710-9.00023-7

Cite this

@inbook{b7238ef202944abbad0a059e198e64ea,

title = "The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia",

abstract = "Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.",

keywords = "Anti-HDV, HCC, HDV epidemiology, HDV lifecycle, HDV therapy, Hepatitis D virus, Prevalence",

author = "Gulnara Aghayeva and Mario Rizzetto and Necati Ormeci and Adela Turcanu and Zaigham Abbas and Essam Bedewy",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/B978-0-443-26710-9.00023-7",

language = "English (UK)",

isbn = "9780443300530",

volume = "1-2",

pages = "655--673",

booktitle = "Hepatology",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - The worldwide medical impact of hepatitis D virus infection

T2 - Focus to Central Asia

AU - Aghayeva, Gulnara

AU - Rizzetto, Mario

AU - Ormeci, Necati

AU - Turcanu, Adela

AU - Abbas, Zaigham

AU - Bedewy, Essam

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.

AB - Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.

KW - Anti-HDV

KW - HCC

KW - HDV epidemiology

KW - HDV lifecycle

KW - HDV therapy

KW - Hepatitis D virus

KW - Prevalence

UR - https://www.scopus.com/pages/publications/85214159236

U2 - 10.1016/B978-0-443-26710-9.00023-7

DO - 10.1016/B978-0-443-26710-9.00023-7

M3 - Chapter

AN - SCOPUS:85214159236

SN - 9780443300530

VL - 1-2

SP - 655

EP - 673

BT - Hepatology

PB - Elsevier

ER -

The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this